RayKnowChina Research Map
Shortlist0

Not yet recruitingIgG4-related diseasePhase 3

Registered title, quoted from ClinicalTrials.gov

Efficacy and Safety of Lenalidomide in Patients With IgG4-Related Disease

An open trial on IgG4-related disease, registered on ClinicalTrials.gov. Led by Chinese PLA General Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorChinese PLA General Hospital中国人民解放军总医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07719543, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 2

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (2 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Pregnancy, breastfeeding, or unwillingness to use effective contraception when applicable.

    Exclusion criterion 8

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07719543, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Adults aged 18 to 75 years at the time of screening.
  • Diagnosis of IgG4-related disease according to the 2019 American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) classification criteria.
  • Patients with IgG4-related disease who have achieved sustained clinical remission following glucocorticoid therapy.
  • No documented IgG4-related disease relapse within the previous 12 months before screening.
  • IgG4-related disease Responder Index (IgG4-RD RI) score of 0 at screening.
  • Receiving stable low-dose glucocorticoid therapy with prednisone-equivalent dose ≤7.5 mg/day for at least 6 months before randomization.
  • Ability to provide written informed consent and comply with study procedures.

Exclusion Criteria:

  • Active IgG4-related disease requiring induction therapy or escalation of immunosuppressive treatment at screening.
  • Previous treatment with lenalidomide or known hypersensitivity to lenalidomide or related compounds.
  • Requirement for prohibited concomitant medications during the study period.
  • Significant uncontrolled infection or active severe infection.
  • Clinically significant hematologic abnormalities, including severe neutropenia or thrombocytopenia.
  • Significant hepatic or renal dysfunction that may affect study participation or drug safety evaluation.
  • History of thromboembolic events or conditions associated with unacceptable thrombotic risk according to investigator assessment.
  • Pregnancy, breastfeeding, or unwillingness to use effective contraception when applicable.
  • Malignancy or other severe medical conditions that may interfere with study participation or outcome assessment.
  • Any condition that, in the investigator's opinion, may compromise participant safety or affect the reliability of study results.

Quoted from ClinicalTrials.gov, NCT07719543, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07719543, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07719543